What is FOXO4-DRI?
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt FOXO4-p53 interaction in senescent cells. It is discussed as a senolytic research peptide. [1][2]
The strongest evidence is preclinical aging and senescence biology. Human anti-aging or disease-treatment outcomes are not established. [1][2]
Senolytic language is high-risk because clearing senescent cells sounds compelling but can affect tissue repair, cancer biology, immune status, and frailty differently across people. [1][2]
What FOXO4-DRI is investigated for
FOXO4-DRI evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Senescent-cell clearance
Injectable
Senescent-cell clearance
Injectable
Age-related tissue and physical function
Injectable
Age-related tissue and physical function
Injectable
Evidence snapshot
Overall confidence
FOXO4-DRI remains a preclinical senolytic concept. Human anti-aging outcomes, dose-ranging, and tissue-specific safety are not established. [1][2][3]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Human senolytic or anti-aging outcomes are not established for FOXO4-DRI. [1][2][3]
Animal / preclinical
Animal and cell studies support the FOXO4-p53 senescence rationale. [1][2][3]
Mechanism support
FOXO4-DRI is intended to disrupt a survival interaction in senescent cells, allowing p53-mediated apoptosis. The concept is senescent-cell removal, not a validated human rejuvenation protocol. [1][2][3]
Forms & administration
FOXO4-DRI is tracked as an injectable senolytic research-market peptide. Intermittent senolytic protocol patterns are separate from approved anti-aging or oncology claims. [8][1]
Dosing & protocols
The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.
Typical Range
Common injectable senolytic protocols usually use 20 mg/kg per dose. [8][1]
Frequency
Common injectable calendars use 3 doses weekly during a short block. [8][1]
Timing Considerations
Morning timing is the common anchor; spacing between intermittent doses matters more than meal timing. [8][1]
Cycle Length
Common FOXO4-DRI blocks run 3 weeks before stopping for reassessment of tolerability and target-outcome notes. [8][1]
What to expect
First 1-2 weeks
Injectable FOXO4-DRI senolytic-style cycles may feel like changes in energy, recovery, inflammatory symptoms, or tissue-repair comfort. [1][2][3][8]
Weeks 4-8
Injectable senolytic-style cycles may leave clearer recovery feel, inflammatory-symptom, energy, or lab-pattern changes after the short cycle. [1][2][3][8]
After stopping
Any injectable FOXO4-DRI senolytic-style signal may persist beyond exposure, so energy and recovery patterns can continue changing after the cycle. [1][2][3][8]
Safety profile
FOXO4-DRI safety centers on senolytic-pathway uncertainty, tissue-repair context, immune/cancer history, and injectable product quality. [1][2][3]
Who FOXO4-DRI is not for
Route-specific avoid and medical-review notes:
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- Senolytic stacks
Dasatinib, quercetin, fisetin, or other senolytic products can stack cell-clearance effects and adverse-event attribution; this is a theoretical pathway caution. [1]
- Oncology / immune therapies
Chemotherapy, targeted cancer therapy, checkpoint inhibitors, or immune biologics can make cell-cycle and immune effects difficult to attribute; this is a theoretical pathway caution. [1]
- Anticoagulants / antiplatelets
Warfarin, DOACs, aspirin, or antiplatelet therapy can increase the consequence of injection bruising or bleeding symptoms; this is a route-specific caution. [1]
Regulatory status
United States
In the U.S. as of 2026-06-21, FOXO4-DRI has no FDA-approved drug product for the reviewed injectable route. Research-market supply and compounded preparations are separate from approval; the 503A row names the current compounding bucket. [8][9][12][13]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Injectable | Not Approved FOXO4-DRI is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [8][9][12][13] | Not Listed FOXO4-DRI is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval. [8][9][12][13] |
Injectable
International
EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [15][16][17][18]
Sports & competition
WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat FOXO4-DRI injectable route as athlete-cleared without sport-specific review. [10][8][9][12][13]
How it works
FOXO4-DRI is designed to disrupt the FOXO4-p53 survival interaction in senescent cells, allowing p53-mediated apoptosis. In plain terms, the goal is to help damaged, non-dividing cells self-remove instead of persisting in tissue. [1][2][3]
Systemic injectable exposure makes that biology a safety problem as well as an opportunity. Senescent cells can participate in wound healing and tissue remodeling, so broad removal claims need human dose, timing, tissue-selectivity, and safety data. The systemic route raises distribution, timing, and off-target questions that cell experiments cannot answer. [1][2][3]
Research gaps & open questions
What the current literature has not yet settled about FOXO4-DRI:
Common questions
Is FOXO4-DRI FDA-approved?
Is FOXO4-DRI a senolytic?
Myths & misconceptions
History & discovery
FOXO4-DRI became visible through senescence research that proposed disrupting the FOXO4-p53 interaction to trigger apoptosis in senescent cells. Its history is almost entirely preclinical. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3]
The landmark preclinical work connected FOXO4 disruption with senescent-cell removal and tissue-homeostasis signals. That milestone created the longevity-market story before human dosing existed. [1][2][3]
Later structural and disease-model work refined the p53 interaction story and showed that eliminating senescent cells can be harmful in some contexts. That changed the history toward caution. [1][2][3]
10 studies
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.
Cell, 2017 Mar 23. animal.
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.
Nat Commun, 2025 Jul 1. review.
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
Circulation, 2023 Feb 21. animal.
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.
Front Bioeng Biotechnol, 2021. in vitro.
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation.
Commun Biol, 2025 Feb 24. in vitro.
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline.
Naunyn Schmiedebergs Arch Pharmacol, 2026 Apr 23. review.
Cellular senescence in the aging and diseased kidney.
J Cell Commun Signal, 2018 Mar. review.
Drugs@FDA/openFDA query for FOXO4-DRI
U.S. Food and Drug Administration. database query.
Compounding and the FDA: Questions and Answers
U.S. Food and Drug Administration. official guidance.
The 2026 List of Prohibited Substances and Methods
World Anti-Doping Agency. regulatory.